The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Sanofi has claimed FDA approval for its anti-CD38 drug isatuximab as a third-line treatment for multiple myeloma, becoming the first direct rival to Johnson & Johnson’s big-selling Darzalex.

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...

Adding isatuximab, an anti-CD38 monoclonal antibody, to bortezomib, lenalidomide, and dexamethasone (VRd) may improve outcomes in transplant-ineligible patients with multiple myeloma. New research ...

In addition, two new chemoimmunotherapy drugs — daratumumab and isatuximab — that specifically target multiple myeloma were ...

DelveInsight’s Refractory Multiple Myeloma pipeline report depicts a robust space with 75+ active players working to develop ...

In September, commenced patient dosing to investigate evorpacept plus SARCLISA® (isatuximab-irfc) and dexamethasone in ...

Binod Dhakal, MD, MS, discusses how the efficacy results observed with ciltacabtagene autoleucel in the CARTITUDE-4 trial compare with other therapies that are used for the treatment of ...

Introduction: Only in recent years has balloon kyphoplasty gained significance in the treatment of vertebral fractures as an adequate minimally invasive vertebral stabilization technique ...

Antisemitic assaults on visiting Israeli soccer fans, and incendiary chants and attacks by some Israelis: Here’s what we know so far about the violence in Amsterdam last week. By Jim ...

The data of 76 patients with 190 kyphoplasty-treated vertebrae were analyzed retrospectively (Figure 3). In our collective, the standard postoperative CT of the kyphoplasty-treated vertebrae ...

The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...